



Fast and simple purification of histidine-tagged proteins using His GraviTrap

Intellectual Property Notice: The Biopharma business of GE Healthcare was acquired by Danaher on 31 March 2020 and now operates under the Cytiva™ brand. Certain collateral materials (such as application notes, scientific posters, and white papers) were created prior to the Danaher acquisition and contain various GE owned trademarks and font designs. In order to maintain the familiarity of those materials for long-serving customers and to preserve the integrity of those scientific documents, those GE owned trademarks and font designs remain in place, it being specifically acknowledged by Danaher and the Cytiva business that GE owns such GE trademarks and font designs.

cytiva.com

GE and the GE Monogram are trademarks of General Electric Company.
Other trademarks listed as being owned by General Electric Company contained in materials that pre-date the Danaher acquisition and relate to products within Cytiva's portfolio are now trademarks of Global Life Sciences Solutions USA LLC or an affiliate doing business as Cytiva.
Cytiva and the Drop logo are trademarks of Global Life Sciences IP Holdco LLC or an affiliate.
All other third-party trademarks are the property of their respective owners.
© 2020 Cytiva
All goods and services are sold subject to the terms and conditions of sale of the supplying company operating within the Cytiva business. A copy of those terms and conditions is available on request. Contact your local Cytiva representative for the most current information.
For local office contact information, visit [cytiva.com/contact](https://www.cytiva.com/contact)

Fast and simple purification of histidine-tagged proteins using His GraviTrap

Anneli Karlsson, Ann Bergh, Marianne Carlsson and Helena Lindgren

GE Healthcare, SE-751 84 Uppsala, Sweden

Introduction

Immobilized metal ion affinity chromatography (IMAC) is a widely-used and highly effective technique that exploits the affinity of histidine-tagged proteins to bind nickel ions attached to chelating separation media such as Ni Sepharose™ 6 Fast Flow.

Histidine-tagged proteins can be quickly and simply purified on His GraviTrap™ columns prepacked with Ni Sepharose 6 Fast Flow without the need for a pump or purification system.

A single column allows purification of approx. 40 mg protein in as little as 20 minutes. Large volumes of clarified or unclarified samples can easily be applied and the purified protein can be eluted in a small volume resulting in a highly concentrated target protein.

Conclusions


His GraviTrap gives the following performance benefits:

- Five-times faster purification than the comparable product from another supplier.
- Possibility to purify both clarified and unclarified samples.
- High protein binding capacity, approx. 40 mg/column.
- No instrumentation, e.g. pump, needed.




Operation

The purification of histidine-tagged proteins on His GraviTrap can be divided into four stages: equilibration, sample application, washing and elution.




Purification of unclarified sample

Unclarified sample



Clarified sample



Purification of unclarified samples

- saves time
- reduces the risk of losing target protein during manual handling
- minimizes degradation and oxidation of sensitive target proteins

Materials

Purification conditions, unless otherwise stated, were:

Columns: His GraviTrap 1 ml Ni-NTA Superflow™ gravity column 1.5 ml (Qiagen™)

Samples: Cell extracts from different strains of *E. coli* containing 0.5 M NaCl and imidazole at a concentration appropriate for each target protein.

Binding buffer: 20 mM sodium phosphate, 0.5 M NaCl, x mM imidazole, pH 7.4 (x = optimized for each target protein)

Elution buffer: 20 mM sodium phosphate, 0.5 M NaCl, 500 mM imidazole, pH 7.4


SDS-PAGE was performed with ExcelGel™ SDS Gradient 8–18 Gels.

High protein binding capacity

Sample: 35 ml clarified *E. coli* BL-21 lysate containing 40 mg GFP-(His)₆

Method:

Equilibration: 10 ml binding buffer (5 mM imidazole)
Sample application: 35 ml sample (5 mM imidazole)
Wash: 20 ml binding buffer (5 mM imidazole)
Elution: 5 ml elution buffer



1. Low molecular weight markers
2. Start material (diluted 1:10)
3. Flow-through (diluted 1:10)
4. Wash (diluted 1:10)
5. Eluate (diluted 1:10)

Results

- Recovery of GFP-(His)₆ was approx. 100 % as calculated using absorbance measurements and the extinction coefficient.
- Purity was comparable with results when just 8 mg sample protein was loaded (see the following experiment).
- The total purification time when 35 ml sample was applied was only 40 minutes

Fast purification and small elution volumes

Sample: 10 ml clarified *E. coli* BL-21 lysate containing 8 mg GFP-(His)₆



Method:

His GraviTrap:

Equilibration: 10 ml binding buffer (45 mM imidazole)
 Sample application: 10 ml sample (45 mM imidazole)
 Wash 1: 10 ml binding buffer (45 mM imidazole)
 Wash 2: 5 ml binding buffer (45 mM imidazole)
 Elution: 3 × 3 ml elution buffer

Ni-NTA Superflow:

Equilibration: 10 ml binding buffer (10 mM imidazole)
 Sample application: 10 ml sample (10 mM imidazole)
 Wash 1: 10 ml binding buffer (20 mM imidazole)
 Wash 2: 5 ml binding buffer (20 mM imidazole)
 Elution: 3 × 3 ml elution buffer



His GraviTrap

1. Low molecular weight markers
2. Start material (diluted 1:10)
3. Flow-through (diluted 1:10)
4. Wash 1
5. Wash 2
6. Eluate 1
7. Eluate 2

Ni-NTA Superflow

8. Flow-through (diluted 1:10)
9. Wash 1
10. Wash 2
11. Eluate 1
12. Eluate 2
13. Eluate 3

Results

- Total purification time for His GraviTrap under native conditions was five-times faster than with Ni-NTA Superflow.
- Recovery during elution, calculated using absorbance measurements and extinction coefficient, was >98 % in the first 3 ml eluate (eluate 1) from His GraviTrap, and approximately 80 % from Ni-NTA Superflow. For complete elution from Ni-NTA Superflow, a total volume of 6–9 ml was needed.
- The purity of the eluates was similar.

Rapid purification of a high molecular weight Histidine-tagged protein


Sample: 20 ml clarified *E. coli* JM109 lysate containing (His)₁₀-TRX-P450 (M_r~ 130 000)

Method:

Equilibration: 10 ml binding buffer (40 mM imidazole)
 Sample application: 20 ml sample (40 mM imidazole)
 Wash: 2 × 10 ml binding buffer (40 mM imidazole)
 Elution: 2 × 3 ml elution buffer

Western Blot:

Electrophoresis and transfer: PhastSystem™ and PhastGel™ Gradient 10–15
 Membrane: Hybond™ ECL
 Primary antibody: Anti-His antibody (mouse)
 Secondary antibody: Anti-mouse IgG, HRP-linked
 Detection: Colorimetric, DAB-enhanced liquid substrate



1. High-Range Rainbow Molecular Weight Markers
2. Start material (diluted 1:20)
3. Flow-through (diluted 1:20)
4. Eluate 1
5. Eluate 2
6. Negative control, (JM109 non-transformed)

Results

- SDS-PAGE analysis shows three major protein bands in the eluted fractions
- Western blot analysis and N-terminal sequencing (data not shown) confirm that each of the three bands in the eluates contains a histidine tag. The low molecular weight bands are truncated forms of the histidine-tagged target protein.
- The whole purification took just 25 minutes.

Acknowledgement

We thank the owner of the clone used in this work: GFP-(His)₆ was provided by Dr. David Drew, Dept. of Biochemistry and Biophysics, Stockholm University.

www.amershambiosciences.com/his

GE Healthcare
Amersham Biosciences AB
Björkgatan 30
751 84 Uppsala
Sweden

Protocols for the comparative studies described are found at
www.amershambiosciences.com/protocol-his

All experiments were performed at GE Healthcare Bio-Sciences, Protein Separations laboratories.

Amersham Biosciences AB, a General Electric Company going to market as GE Healthcare.

ExcelGel, GraviTrap, Hybond, PhastGel, PhastSystem and Sepharose are trademarks of GE Healthcare Ltd, a General Electric Company. GE and GE monogram are trademarks of General Electric Company.

Qiagen is a trademark of the Qiagen group. Superflow is a trademark of Sterogene Bioseparations Inc.

All goods and services are sold subject to the terms and conditions of sale of the company within GE Healthcare which supplies them. GE Healthcare reserves the right, subject to any regulatory and contractual approval, if required, to make changes in specifications and features shown herein, or discontinue the product described at any time without notice or obligation. Contact your local GE Healthcare representative for the most current information.

Purification and preparation of fusion proteins and affinity peptides comprising at least two adjacent histidine residues may require a license under US pat 5,284,933 and US pat 5,310,663, including corresponding foreign patents (assigne: Hoffman La Roche, Inc).

© 2005 General Electric Company - All rights reserved.



imagination at work